Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors
AssigneeSuven Life Sciences Limited
InventorsRamakrishna NIROGI, Anil Karbhari SHINDE, Abdul Rasheed MOHAMMED, Pradeep JAYARAJAN, Gopinadh BHYRAPUNENI, Venkateswarlu JASTI
Life of this patent
Estimating the term…
Abstract
The present invention relates to the combination of histamine-3 receptor inverse agonist and acetylcholinesterase inhibitor. Also, the present invention provides histamine-3 receptor (H3R) inverse agonist, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitor and their use in the treatment of cognitive disorders. The present invention further provides the pharmaceutical composition containing the said combination.
Claims31
A combination comprising a histamine-3 receptor inverse agonist and an acetylcholinesterase inhibitor;
- wherein the histamine-3 receptor inverse agonist is selected from the group consisting of:
- N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide;
- N-[4-(1-Cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide;
- and
- N-[4-(1-Isopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide;
- or a pharmaceutically acceptable salt thereof.
A combination comprising N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride and donepezil hydrochloride.
The method of treatment as claimed in 11, wherein the cognitive disorder is selected from Alzheimer's disease, schizophrenia, Parkinson's disease, Lewy body dementia, vascular dementia, frontotemporal dementia, Down syndrome and Tourette's syndrome.
(canceled)
(canceled)
(canceled)
A method of treating Alzheimer's disease in a patient comprising the step of administering to said patient a therapeutically effective amount of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof and acetylcholinesterase inhibitor.
A method of treating Alzheimer's disease in a patient on stable treatment with acetylcholinesterase inhibitor comprising the step of administering to said patient a therapeutically effective amount of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.